To achieve the main objective of the study, we evaluated SFRP5, WNT5A and PPARγ mRNA expression in adipose tissue (SAT and VAT) classifying the cohort into NAFLD grades. This evidence concerns the gene SFRP5 and metabolic dysfunction-associated steatotic liver disease.